222 related articles for article (PubMed ID: 7761274)
1. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
[TBL] [Abstract][Full Text] [Related]
2. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
3. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
4. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
5. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine therapy for thyroid volume reduction of large goitres.
Bachmann J; Kobe C; Bor S; Rahlff I; Dietlein M; Schicha H; Schmidt M
Nucl Med Commun; 2009 Jun; 30(6):466-71. PubMed ID: 19381116
[TBL] [Abstract][Full Text] [Related]
7. What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?
Gotthardt M; Rubner C; Bauhofer A; Berce F; Oyen WJ; Goecke J; Pfestroff A; Schlieck A; Corstens FH; Béhé M; Behr TM
Nuklearmedizin; 2006; 45(5):206-12. PubMed ID: 17043731
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
10. [Changes in thyroid volume after radioactive iodine therapy in patients with single toxic thyroid nodule].
Gołkowski F; Jabrocka-Hybel A; Huszno B
Przegl Lek; 2005; 62(5):284-6. PubMed ID: 16334533
[TBL] [Abstract][Full Text] [Related]
11. [Radioiodine therapy of funcitonal autonomy using the functional autonomous volume].
Seeger T; Emrich D; Sandrock D
Nuklearmedizin; 1995 Aug; 34(4):135-40. PubMed ID: 7675642
[TBL] [Abstract][Full Text] [Related]
12. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of solitary autonomous thyroid nodules treated with 131I.
Goldstein R; Hart IR
N Engl J Med; 1983 Dec; 309(24):1473-6. PubMed ID: 6646172
[TBL] [Abstract][Full Text] [Related]
14. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
Moka D; Voth E; Schicha H
Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy and thyrostatic drugs and iodine.
Moka D; Dietlein M; Schicha H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
[TBL] [Abstract][Full Text] [Related]
16. [Radioiodine therapy of functional autonomy of the thyroid gland. Treatment results in view of pretreatment scintigraphic diagnosis and early response of triiodothyronine levels to treatment].
Langhammer HR; Laubenbacher C; Hirsch C; Klingele C; Spyra JL; Senekowitsch-Schmidtke R; Schwaiger M
Med Klin (Munich); 1999 Aug; 94(8):415-24. PubMed ID: 10495620
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
Listewnik MH
Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
[TBL] [Abstract][Full Text] [Related]
18. The relationship between 24 h/4 h radioiodine-131 uptake ratio and outcome after radioiodine therapy in 1402 patients with solitary autonomously functioning thyroid nodules.
Filesi M; Travascio L; Montesano T; Di Nicola AD; Colandrea M; Ugolini F; Bruno R; Gross MD; Vestri A; Rubello D; Ronga G
Ann Nucl Med; 2009 May; 23(3):229-34. PubMed ID: 19322512
[TBL] [Abstract][Full Text] [Related]
19. Optimized dose planning of radioiodine therapy of benign thyroidal diseases.
Bockisch A; Jamitzky T; Derwanz R; Biersack HJ
J Nucl Med; 1993 Oct; 34(10):1632-8. PubMed ID: 8410273
[TBL] [Abstract][Full Text] [Related]
20. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
